“`html
Cancer • Kidney Injury • Immunotherapy • Hematologic Disease • Transplantation
Cancer Treatment Has Changed.
Kidney Care Must Change With It.
The Harvard Onconephrology Symposium 2026
focuses on one of the most complex intersections in contemporary medicine:
the management of kidney disease in patients with cancer and hematologic disorders.
Modern cancer therapies have transformed oncology while introducing new
diagnostic and therapeutic challenges involving acute kidney injury,
glomerular disease, drug toxicity, monoclonal disorders, immune-mediated injury
and transplantation.
Through expert lectures, clinical discussions and case-focused sessions,
the symposium examines how nephrology and cancer care increasingly intersect
throughout diagnosis, treatment and long-term patient management.
One Patient.
Multiple Clinical Layers.
Understand the Cancer Context
Consider the underlying malignancy, hematologic disorder,
disease status and current cancer treatment strategy.
Define the Renal Problem
AKI, altered GFR, proteinuria, glomerular disease,
electrolyte abnormalities or treatment-associated renal injury.
Identify Treatment-Related Toxicity
Evaluate chemotherapy, immunotherapy, cellular therapies
and other contemporary cancer treatments as potential contributors.
Determine What Is Driving the Injury
Consider immune injury, drug toxicity, monoclonal processes,
cancer-associated disease and transplant-related mechanisms.
Balance Cancer Control & Kidney Protection
Navigate treatment continuation, modification, rechallenge,
renal protection and multidisciplinary care.
The Multidisciplinary Core
NEPHROLOGY
Kidney injury, glomerular disease, GFR assessment,
transplantation and renal-protective strategies.
ONCOLOGY
Modern cancer treatment, treatment-related toxicity
and multidisciplinary cancer care.
HEMATOLOGY
Plasma-cell disorders, monoclonal gammopathies,
amyloidosis and light-chain disease.
CANCER THERAPEUTICS
Chemotherapy, immunotherapy, cellular therapies
and targeted treatment approaches.
Onconephrology Symposium 2026
September 17–18, 2026
2 Days
Videos + Slides
Nephrology • Oncology • Hematology • Pharmacology
2026
What You’ll Explore
Build a broader understanding of renal complications associated
with malignancy and contemporary cancer treatment.
Cancer-Associated Kidney Injury
Diagnosis and management of renal complications in patients with cancer.
Glomerular Disease
Cancer-associated glomerular disorders and evolving treatment considerations.
Thrombotic Microangiopathy
Evolving diagnostic and therapeutic concepts in TMA.
Monoclonal Disorders
MGRS, immunoglobulin-mediated injury, amyloidosis
and plasma-cell disease.
Cancer Therapy Nephrotoxicity
Renal toxicity associated with chemotherapy and emerging cancer therapies.
Cellular & Immune Therapies
CAR-T, immune checkpoint inhibitors and other modern treatment approaches.
Kidney Transplantation & Cancer
Complex transplant considerations in patients with malignancy.
Reno-Protective Strategies
Strategies for preserving kidney function during cancer treatment.
New Treatments.
New Renal Challenges.
The program examines renal complications arising alongside
rapid advances in cancer treatment and cellular therapy.
September 17, 2026
HSCT, Immunotherapy & Cancer-Associated Kidney Injury
Shruti Gupta • Raad Chowdhury
Joseph Bonventre
Corey Cutler
Sumithra Vasu
Anuja Java
Sandra Herrmann
Sessions address ICI-associated acute kidney injury, biomarkers,
treatment strategies, non-renal immune-related adverse events
and multidisciplinary approaches to glomerular disease.
CAR-T, Cancer Therapy & Kidney Function
Sarah Nikiforow
Allison Betof
Edgar Jaimes
David Leaf
Aisha Shaikh
Abhijat Kitchlu
Glomerular Disease & Cancer-Associated Nephrotoxicity
Astrid Weins
Api Chewcharat
María José Soler
Sujal Shah
Biruh Workeneh • Astrid Weins • Harish Seethapathy • Aisha Shaikh
Samantha Gelfand
September 18, 2026
Vaishali Sanchorawala
Anju Nohria
Nikhil Munshi
Samih H. Nasr
Christophe Sirac
The Onconephrology Jeopardy Challenge
Jorge J. Castillo
Nelson Leung
Christopher Blosser • Raad Chowdhury
Christopher Blosser
The War Against Light Chains
The Onconephrology Landscape
Cancer-Associated AKI
HSCT & Thrombotic Microangiopathy
Immune Checkpoint Inhibitor Kidney Injury
CAR-T & Cellular Therapy Toxicities
Chemotherapy Dosing & Nephrotoxicity
Cancer-Associated Glomerular Disease
Amyloidosis & Plasma-Cell Disorders
MGRS & Immunoglobulin-Mediated Injury
Kidney Transplantation & Cancer
Palliative & Multidisciplinary Onconephrology Care
Program Leadership
Raad Chowdhury, MD, FASN
Medical Director of Onconephrology,
Brigham and Women’s/Dana-Farber Cancer Institute
APD, Mass General Brigham Nephrology Fellowship,
Harvard Medical School
Shruti Gupta, MD, MPH
Director of Onconephrology,
Brigham and Women’s/Dana-Farber Cancer Institute
Assistant Professor, Harvard Medical School
For Multidisciplinary
Cancer & Kidney Care
Particularly relevant for healthcare professionals involved
in the care of patients with malignancy and renal complications.
Modern Cancer Therapy Creates
New Kidney Challenges.
As cancer treatment evolves, clinicians increasingly encounter
renal complications associated with chemotherapy, immunotherapy,
cellular therapy, monoclonal disorders and complex hematologic disease.
Effective management often requires balancing cancer control with
preservation of kidney function while navigating diagnostic uncertainty,
drug dosing, treatment toxicity and multidisciplinary decision-making.
Understand cancer-associated renal complications
Review modern cancer therapy nephrotoxicity
Explore monoclonal and plasma-cell kidney disease
Examine challenging multidisciplinary cases
Connect nephrology with contemporary cancer care
“`
Reviews
There are no reviews yet.